{"id":"sulfamethoxazole-trimethoprim-injectable-product","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Rash"},{"rate":"2-4","effect":"Nausea"},{"rate":"1-3","effect":"Vomiting"},{"rate":"1-2","effect":"Hyperkalemia"},{"rate":"0.1-0.5","effect":"Stevens-Johnson syndrome"},{"rate":"1-2","effect":"Hepatotoxicity"},{"rate":"1-2","effect":"Bone marrow suppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sulfamethoxazole is a sulfonamide that inhibits dihydropteroate synthase, preventing the condensation of para-aminobenzoic acid (PABA) with pteridine to form dihydropteroate. Trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolate to tetrahydrofolate. Together, they create a sequential blockade of the bacterial folate synthesis pathway, resulting in bactericidal activity against a broad spectrum of gram-positive and gram-negative organisms.","oneSentence":"Sulfamethoxazole and trimethoprim are synergistic antibiotics that inhibit bacterial folate synthesis by blocking dihydropteroate synthase and dihydrofolate reductase, respectively.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:12.233Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Urinary tract infections"},{"name":"Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment"},{"name":"Bacterial infections (gram-positive and gram-negative)"},{"name":"Toxoplasmosis"}]},"trialDetails":[{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT04368559","phase":"PHASE3","title":"Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mundipharma Research Limited","startDate":"2020-05-11","conditions":"Candidemia, Mycoses, Fungal Infection","enrollment":602},{"nctId":"NCT04263792","phase":"PHASE1","title":"[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-02-07","conditions":"Bacterial Infections","enrollment":20},{"nctId":"NCT03424525","phase":"PHASE1","title":"11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-02-01","conditions":"Bacterial Infections","enrollment":16},{"nctId":"NCT03178149","phase":"PHASE1","title":"A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Astellas Institute for Regenerative Medicine","startDate":"2018-07-13","conditions":"Age-Related Macular Degeneration","enrollment":42},{"nctId":"NCT07228702","phase":"PHASE1","title":"Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Vancouver Coastal Health","startDate":"2025-11","conditions":"Non-Tuberculous Mycobacterial (NTM) Pneumonia, Mycobacterium Abscessus Infection","enrollment":1},{"nctId":"NCT06841705","phase":"PHASE2","title":"Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial","status":"RECRUITING","sponsor":"Shilpa Grover, MD, MPH","startDate":"2025-07-15","conditions":"Immune Checkpoint Inhibitor-Related Colitis","enrollment":80},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT06953271","phase":"PHASE4","title":"Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection","status":"NOT_YET_RECRUITING","sponsor":"Women and Infants Hospital of Rhode Island","startDate":"2025-05-15","conditions":"Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis)","enrollment":164},{"nctId":"NCT05719285","phase":"PHASE4","title":"Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2022-12-06","conditions":"Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence","enrollment":100},{"nctId":"NCT03508921","phase":"PHASE4","title":"Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-07-01","conditions":"Overactive Bladder, Urinary Tract Infections","enrollment":22},{"nctId":"NCT03173053","phase":"NA","title":"S. Aureus Decolonization in HPN Patients.","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2018-02-08","conditions":"Staphylococcus Aureus, Motility Disorder","enrollment":63},{"nctId":"NCT00000715","phase":"PHASE3","title":"A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia in AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Pneumonia, Pneumocystis Carinii, HIV Infections","enrollment":240},{"nctId":"NCT01192789","phase":"NA","title":"Community Case Management of the Severe Pneumonia With Oral Amoxicillin in Children 2-59 Months of Age","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2008-02","conditions":"Severe Pneumonia","enrollment":4070},{"nctId":"NCT00023244","phase":"PHASE2","title":"Steroid Withdrawal in Pediatric Kidney Transplant Recipients","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-01","conditions":"End-Stage Renal Disease","enrollment":274},{"nctId":"NCT00004216","phase":"PHASE1","title":"VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy","status":"COMPLETED","sponsor":"Vion Pharmaceuticals","startDate":"1999-08","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sulfamethoxazole / Trimethoprim Injectable Product","genericName":"Sulfamethoxazole / Trimethoprim Injectable Product","companyName":"Fundacion Clinic per a la Recerca Biomédica","companyId":"fundacion-clinic-per-a-la-recerca-biom-dica","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sulfamethoxazole and trimethoprim are synergistic antibiotics that inhibit bacterial folate synthesis by blocking dihydropteroate synthase and dihydrofolate reductase, respectively. Used for Urinary tract infections, Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Bacterial infections (gram-positive and gram-negative).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}